Zevra Therapeutics

Zevra Therapeutics company information, Employees & Contact Information

We are a rare disease therapeutics company leading with science to make life-changing therapeutics available to patients with significant unmet needs. We involve key thought leaders, physicians, patients, care partners, and advocacy groups in all of our clinical and regulatory development strategies. With a keen understanding that drug development often requires creative solutions, we have the insight and expertise to forge new pathways to success that others have missed. By following the data without bias, our transparent narratives and common-sense perspective have successfully overcome complex development challenges to make much-needed therapies available to patients. Nimble and dauntless, we push boundaries beyond what is thought to be possible and advance new therapies that have the potential to bring meaningful improvement to patients’ lives.

Company Details

Employees
64
Founded
-
Address
1180 Celebration Boulevard, Celebration,fl 34747,united States
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
jobs.
HQ
Celebration, FL
Looking for a particular Zevra Therapeutics employee's phone or email?

Zevra Therapeutics Questions

News

Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call - GlobeNewswire

Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call GlobeNewswire

Zevra Therapeutics (NASDAQ: ZVRA) schedules Q3 2025 earnings call at 4:30 p.m. ET - Stock Titan

Zevra Therapeutics (NASDAQ: ZVRA) schedules Q3 2025 earnings call at 4:30 p.m. ET Stock Titan

Zevra Therapeutics Submits Marketing Authorization Application to EMA for Arimoclomol in Niemann-Pick Disease Type C - Quiver Quantitative

Zevra Therapeutics Submits Marketing Authorization Application to EMA for Arimoclomol in Niemann-Pick Disease Type C Quiver Quantitative

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) The Manila Times

38,000-Share Inducement: Zevra Therapeutics Awards Options to Two New Hires, Vesting Over 4 Years - Stock Titan

38,000-Share Inducement: Zevra Therapeutics Awards Options to Two New Hires, Vesting Over 4 Years Stock Titan

Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM) - Yahoo Finance

Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM) Yahoo Finance

First Drug to Stop NPC Disease Progression: Zevra's MIPLYFFA Shows Breakthrough Results in 270 Patients - Stock Titan

First Drug to Stop NPC Disease Progression: Zevra's MIPLYFFA Shows Breakthrough Results in 270 Patients Stock Titan

All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company’s Director Nominees - Yahoo Finance

All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company’s Director Nominees Yahoo Finance

Disease Progression Slowed: Zevra's MIPLYFFA Shows Breakthrough Results in Rare Niemann-Pick Disease Trial - Stock Titan

Disease Progression Slowed: Zevra's MIPLYFFA Shows Breakthrough Results in Rare Niemann-Pick Disease Trial Stock Titan

Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sod - GlobeNewswire

Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sod GlobeNewswire

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C - GlobeNewswire

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C GlobeNewswire

Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® - GlobeNewswire

Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® GlobeNewswire

Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million - GlobeNewswire

Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million GlobeNewswire

Zevra Therapeutics Urges Stockholders to Vote "FOR" Qualified Directors Amid Proxy Contest Concerns - Nasdaq

Zevra Therapeutics Urges Stockholders to Vote "FOR" Qualified Directors Amid Proxy Contest Concerns Nasdaq

Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million - GlobeNewswire

Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million GlobeNewswire

Zevra Therapeutics Announces Organizational Changes - GlobeNewswire

Zevra Therapeutics Announces Organizational Changes GlobeNewswire

Zevra Reports Second Quarter 2025 Financial Results and Corporate Update - Yahoo Finance

Zevra Reports Second Quarter 2025 Financial Results and Corporate Update Yahoo Finance

Zebra Showcases AI for the Frontline at Inaugural Frontline AI Summit and Annual ZONE Conference - Yahoo Finance

Zebra Showcases AI for the Frontline at Inaugural Frontline AI Summit and Annual ZONE Conference Yahoo Finance

Zebra Technologies and Tulip Collaboration Delivers Mobile-First Experience to the Frontline - Yahoo Finance

Zebra Technologies and Tulip Collaboration Delivers Mobile-First Experience to the Frontline Yahoo Finance

Mary McDowell Joins Zebra Technologies Board of Directors - Yahoo Finance

Mary McDowell Joins Zebra Technologies Board of Directors Yahoo Finance

ODW Logistics Expects to Improve Pick Rates by 42% With Zebra Technologies - Yahoo Finance

ODW Logistics Expects to Improve Pick Rates by 42% With Zebra Technologies Yahoo Finance

Zebra Technologies to Release Third Quarter Results on Oct. 28 - Business Wire

Zebra Technologies to Release Third Quarter Results on Oct. 28 Business Wire

Indianapolis Colts Team Up with Zebra Technologies for Real-Time Player Performance Insights - Yahoo Finance

Indianapolis Colts Team Up with Zebra Technologies for Real-Time Player Performance Insights Yahoo Finance

Zebra Technologies Jumps to Top Ten on Fast Company’s 2025 Best Workplaces for Innovators List - Business Wire

Zebra Technologies Jumps to Top Ten on Fast Company’s 2025 Best Workplaces for Innovators List Business Wire

Zebra Technologies to Acquire Elo to Accelerate Connected Frontline Experiences - Yahoo Finance

Zebra Technologies to Acquire Elo to Accelerate Connected Frontline Experiences Yahoo Finance

Zebra Study with Oxford Economics: Automation of Workflows Drives 20% Increase in Productivity - Business Wire

Zebra Study with Oxford Economics: Automation of Workflows Drives 20% Increase in Productivity Business Wire

Zebra Technologies Completes Acquisition of Elo to Accelerate Connected Frontline Experiences - Business Wire

Zebra Technologies Completes Acquisition of Elo to Accelerate Connected Frontline Experiences Business Wire

Zebra Technologies to Present at Investor Conferences - Business Wire

Zebra Technologies to Present at Investor Conferences Business Wire

Zevra Therapeutics’ President and Chief Executive Officer - GlobeNewswire

Zevra Therapeutics’ President and Chief Executive Officer GlobeNewswire

Zebra Technologies Unveils Solutions Advancing Intelligent Automation at ProMat 2025 - Business Wire

Zebra Technologies Unveils Solutions Advancing Intelligent Automation at ProMat 2025 Business Wire

Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders - PR Newswire

Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders PR Newswire

Zebra Technologies Completes Acquisition of Photoneo - Business Wire

Zebra Technologies Completes Acquisition of Photoneo Business Wire

Zevra Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023 - Yahoo Finance

Zevra Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023 Yahoo Finance

Zevra Therapeutics to Acquire Acer Therapeutics, Expanding - GlobeNewswire

Zevra Therapeutics to Acquire Acer Therapeutics, Expanding GlobeNewswire

Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility - GlobeNewswire

Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility GlobeNewswire

Zebra Technologies Backs Xemelgo's AI Manufacturing Platform Used by Yamaha and SEKISUI - Stock Titan

Zebra Technologies Backs Xemelgo's AI Manufacturing Platform Used by Yamaha and SEKISUI Stock Titan

United States Postal Service Recognizes Zebra Technologies with Supplier Performance Award - Stock Titan

United States Postal Service Recognizes Zebra Technologies with Supplier Performance Award Stock Titan

KemPharm Announces Corporate Name Change to Zevra Therapeutics - Yahoo Finance

KemPharm Announces Corporate Name Change to Zevra Therapeutics Yahoo Finance

NFL Next Gen Stats Super Bowl LIX Preview Presented by Zebra Technologies - Business Wire

NFL Next Gen Stats Super Bowl LIX Preview Presented by Zebra Technologies Business Wire

ZVRA - Zevra Therapeutics Inc Latest Stock News & Market Updates - Stock Titan

ZVRA - Zevra Therapeutics Inc Latest Stock News & Market Updates Stock Titan

Zebra Technologies Appoints Rob Armstrong as Chief Marketing Officer - Business Wire

Zebra Technologies Appoints Rob Armstrong as Chief Marketing Officer Business Wire

Satish Dhanasekaran Joins Zebra Technologies Board of Directors - Business Wire

Satish Dhanasekaran Joins Zebra Technologies Board of Directors Business Wire

Top Zevra Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant